



Why Catalyst Clinical Research Selected Medidata CTMS: Fast Data Insights Improved Productivity, Client Centricity

Catalyst Clinical Research, a full-service CRO, has a clear focus on helping pharmaceutical clients deliver better patient care. Catalyst has been an early adopter of Medidata's full life cycle management solutions for end-to-end clinical management. The company now includes Medidata in its core of Clinical Trial Management System (CTMS) capabilities, including on-demand access to data insights. Catalyst had a long history of providing high-quality clinical trial services.

THE CHALLENGE: IMPROVE ACCESS TO DATA, COLLABORATION ACROSS FUNCTIONS

As Catalyst's business grew, the company reached a point at which it no longer could manage clinical trial activities for its clients using its homegrown solution, which included spreadsheets, various trackers, and email communications with study team members. It was time to invest in a CTMS that could give study managers the oversight they needed to spot issues early before they became major problems.

In evaluating its options for a CTMS, Catalyst was seeking a solution that would be welcomed by sites and sponsors for its ease of use and that would give all team members access to a "sole source of the truth" to support efficient study management, issue management, and site monitoring. More specifically, the CTMS would need to:

- **Unify data through a single platform.** The system would have to integrate with Catalyst's technology and workflows so that it could capture and harmonize information across functions and serve as the system of record for a trial. The benefits would extend from a clinical research associate (CRA) seeking information on monitoring activities to a study manager searching for details on protocol deviations.
- **Enhance predictive capabilities.** Users need the ability to detect issues quickly so that they can be addressed before they become major problems.
- **Incorporate a powerful reporting engine.** Catalyst and its sponsors need to be able to pull data whenever they need it and to produce reports that draw on data from across studies and include powerful visuals.
- **Be adaptable and scalable.** Catalyst's journey with sponsors begins in early development, and therefore, companies are looking for systems that can grow with them as their compound progresses from early phase trials to late phase ones.
- **Be familiar to sponsors and sites.** Catalyst wanted the CTMS to be readily adopted and familiar to sites.

NEW TO MEDIDATA CTMS: AD HOC REPORTING

See your data in a whole new way – in cross-study and multi-level views. Users can:

- Create intuitive visuals
- Perform calculations
- Build custom dashboards

With access to all their CTMS data, users can combine, compare, calculate, and evaluate it – all within an easy-to-configure tool.

THE SOLUTION: MEDIDATA CTMS

Among other things, Catalyst was impressed by the results of their research indicating that sponsors – particularly large institutions doing work in oncology – had a strong preference for Medidata's Rave EDC as their EDC technology. Ultimately, Medidata CTMS "checked all the boxes for Catalyst decision makers," as reported by Keya Watkins, Global Head, Clinical Development at Catalyst, and the company migrated to the system.

Medidata also offered Catalyst seamless integration between CTMS and other Medidata systems (such as Rave EDC, Coder, and eTMF), all of which are unified on a single platform: the Medidata Rave Clinical Cloud™. This allows data to flow smoothly between these applications.

As Catalyst was relying on Medidata CTMS as the backbone of its clinical trial operating system, the Medidata team provided the Catalyst team with visibility to its long-term vision and strategy for the platform.

THE BENEFITS: GREATER PRODUCTIVITY, CUSTOMER CENTRICITY

Catalyst was committed to being as self-sufficient as possible with its applications on the Medidata Rave Clinical Cloud, so it took advantage of Medidata's accreditation program. Catalyst was thus able to perform many of its own builds and reduce start-up times. Specifically with respect to Medidata CTMS, Catalyst has benefited from:

- **Improved productivity.** Catalyst notes that teams can now work more efficiently and cohesively. Organizational silos have been reduced or eliminated, and information only needs to be entered once and is available throughout the system. For example, the addition of an investigator into the system is automatically reflected in artifacts such as trip reports and issue management records.
- **Streamlined workflows.** Medidata CTMS eliminates spreadsheet trackers and reduces delays in sharing information. A monitor might, for example, identify an issue and enter it into the Issue Management function. The study manager would receive an alert about it and could then use the system to assign it to a resource. That resource would receive an alert and, once the issue is resolved, be able to mark the task as completed.
- **Customer centricity.** Catalyst's sponsors have quick access to data insights from multiple sources, which facilitates quick decision-making and

Medidata, a Dassault Systèmes company, is leading the digital transformation of life sciences™.

Discover more at www.medidata.com and follow us [@medidata](https://twitter.com/medidata) or info@mdsol.com | +1 866 515 6044